Adding elotuzumab to standard treatment for myeloma reduced disease progression

ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma, met its primary endpoints. The two-year progression-free survival rate was 41% in the elotuzumab group versus 27% in the control group.

Presented by Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, at the 20th Congress of the European Hematology Association (EHA)

Year of Production:
Running Time:


Comments are closed.